The EASL General Assembly will take place on Friday, 29 May 2026, from 18:45 to 20:00 during EASL Congress 2026 in Barcelona. The meeting will be held in person in the Mondelli Room. Please note that an active EASL Membership and EASL Congress registration is required to attend. The General Assem…
We are excited to announce the launch of the call for nominations and applications for three prestigious awards: the EASL Community Award 2026, the EASL Emerging Leader Award 2026, and the EASL Excellence in Liver Care Award 2026. These awards recognise outstanding contributions and leadership in…
This ambitious collaboration between academic, clinical, and industry partners aims to transform how liver diseases are diagnosed and treated by developing innovative and cost-effective tools for early diagnosis and personalized care, with the goal of improving patient outcomes. [vc_custom_headin…
The ambition of the LiverScreen Consortium has been realised with the screening of more than 30.000 participants from the general population across 9 different European Countries and the development & validation of the Liver Risk Score, bringing forward significant new & important knowledge to th…
DECISION strives to better understand the pathophysiology of decompensated cirrhosis leading to acute-on-chronic liver failure (ACLF) at the systems level by taking advantage of already existing large and clinically well-characterized patient cohorts. The ultimate goal is to significantly reduce …
22 European institutions join forces in MICROB-PREDICT to improve the prevention and treatment of chronic liver disease (cirrhosis). We aim to identify microbiome-based biomarkers and mechanisms that predict in advance when the body can no longer compensate for the dysfunctional liver (decompensa…
A-TANGO strives to increase the survival rate with G-TAK – a novel combinatorial therapy, and to decrease the burden on the national healthcare systems, which is caused by a large percentage of patients who never recover fully and require long-term care.[vc_custom_heading text=”Wednesday…
THRIVE is an EU-founded initiative that brings together a strong and multidisciplinary team with 13 partners, from 8 countries, with complementary expertise in liver cancer research and in the use of cutting-edge technologies. The overall aim of the THRIVE project is to improve the outcome of bot…
GENIAL is a pioneering initiative targeting alcohol-related liver cancer (ALD-HCC). Our primary goal is to identify genetic and environmental factors contributing to ALD-HCC risk and unravel how their interactions drive alcohol-related liver carcinogenesis. By pinpointing individuals at risk, GEN…
The LIVERAIM project’s overall goal is to set up a screening platform to detect cases of liver disease early on, so that patients can take steps to protect their liver before it’s too late. As the silent phase of the disease can last for two decades, there is a clear window of opportunity to take…
